AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (864.2 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Adaptive response of resistant cancer cells to chemotherapy

Yi-Jye Chern1,2, Isabella T. Tai1,2 ( )
Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia V5Z1L3, Canada
Michael Smith Genome Sciences Center, British Columbia Cancer Agency, Vancouver, British Columbia V5Z1L3, Canada
Show Author Information

Abstract

Despite advances in cancer therapeutics and the integration of personalized medicine, the development of chemoresistance in many patients remains a significant contributing factor to cancer mortality. Upon treatment with chemotherapeutics, the disruption of homeostasis in cancer cells triggers the adaptive response which has emerged as a key resistance mechanism. In this review, we summarize the mechanistic studies investigating the three major components of the adaptive response, autophagy, endoplasmic reticulum (ER) stress signaling, and senescence, in response to cancer chemotherapy. We will discuss the development of potential cancer therapeutic strategies in the context of these adaptive resistance mechanisms, with the goal of stimulating research that may facilitate the development of effective cancer therapy.

Keywords

Cancerchemotherapyautophagysenescencechemoresistanceadaptive responseER stress signaling

References

1

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
Crossref Google Scholar
2

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
Crossref Google Scholar
3

Biesecker LG, Burke W, Kohane I, Plon SE, Zimmern R. Next-generation sequencing in the clinic: are we ready? Nat Rev Genet. 2012; 13: 818-24.
Crossref Google Scholar
4

Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012; 12: 323-34.
Crossref Google Scholar
5

Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481: 306-13.
Crossref Google Scholar
6

Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011; 29: 3185-93.
Crossref Google Scholar
7

Hamburg M, Collins F. The path to personalized medicine. N Engl J Med. 2010; 363: 301-4.
Crossref Google Scholar
8

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13: 714-26.
Crossref Google Scholar
9

Crawford DR, Davies KJ. Adaptive response and oxidative stress. Environ Health Perspect. 1994; 102 Suppl: 25-8.
Crossref Google Scholar
10

Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010; 40: 280-93.
Crossref Google Scholar
11

Yin X, Dewille JW, Hai T. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene. 2008; 27: 2118-27.
Crossref Google Scholar
12

Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017; 168: 692-706.
Crossref Google Scholar
13

Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006; 10: 51-64.
Crossref Google Scholar
14

Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003; 112: 1809-20.
Crossref Google Scholar
15

Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25: 717-29.
Crossref Google Scholar
16

Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011; 8: 528-39.
Crossref Google Scholar
17

Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012; 11: 709-30.
Crossref Google Scholar
18

Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016; 35: 23.
Crossref Google Scholar
19

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6: 392-401.
Crossref Google Scholar
20

Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21: 488-503.
Crossref Google Scholar
21

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
Crossref Google Scholar
22

Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6: 327-38.
Crossref Google Scholar
23

Singleton DC, Harris AL. Microenvironmental induced essentiality of autophagy. Clin Cancer Res. 2013; 19: 2791-3.
Crossref Google Scholar
24

Hu YL, Jahangiri A, DeLay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 2012; 72: 4294-9.
Crossref Google Scholar
25

Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007; 26: 2527-39.
Crossref Google Scholar
26

Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouysségur J, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009; 29: 2570-81.
Crossref Google Scholar
27

Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13: 132-41.
Crossref Google Scholar
28

Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012; 72: 1773-83.
Crossref Google Scholar
29

Guo XL, Li D, Sun K, Wang J, Liu Y, Song JR, et al. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma. J Mol Med. 2013; 91: 473-83.
Crossref Google Scholar
30

Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O’Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res. 2013; 19: 2995-3007.
Crossref Google Scholar
31

Kim KW, Paul P, Qiao J, Chung DH. Autophagy mediates paracrine regulation of vascular endothelial cells. Lab Invest. 2013; 93: 639-45.
Crossref Google Scholar
32

Kim KW, Paul P, Qiao J, Lee S, Chung DH. Enhanced autophagy blocks angiogenesis via degradation of gastrin-releasing peptide in neuroblastoma cells. Autophagy. 2013; 9: 1579-90.
Crossref Google Scholar
33

Yang SY, Kim NH, Cho YS, Lee H, Kwon HJ. Convallatoxin, a dual inducer of autophagy and apoptosis, inhibits angiogenesis in vitro and in vivo. PLoS One. 2014; 9: e91094.
Crossref Google Scholar
34

Poluzzi C, Casulli J, Goyal A, Mercer TJ, Neill T, Iozzo RV. Endorepellin evokes autophagy in endothelial cells. J Biol Chem. 2014; 289: 16114-28.
Crossref Google Scholar
35

Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta. 2006; 1766: 23-41.
Crossref Google Scholar
36

Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006; 116: 1955-62.
Crossref Google Scholar
37

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 15: 68-74.
Crossref Google Scholar
38

von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017; 10: 76.
Crossref Google Scholar
39

Yan Y, Chen X, Wang X, Zhao Z, Hu W, Zeng S, et al. The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer. J Exp Clin Cancer Res. 2019; 38: 171.
Crossref Google Scholar
40

Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009; 174: 2023-34.
Crossref Google Scholar
41

Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, et al. Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy. Cell Cycle. 2009; 8: 1654-8.
Crossref Google Scholar
42

Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 2010; 9: 3256-76.
Crossref Google Scholar
43

Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 2010; 9: 3515-33.
Crossref Google Scholar
44

Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009; 8: 3984-4001.
Crossref Google Scholar
45

Liao J-K, Zhou B, Zhuang X-M, Zhuang PL, Zhang DM, Chen WL. Cancer-associated fibroblasts confer cisplatin resistance of tongue cancer via autophagy activation. Biomed Pharmacother. 2018; 97: 1341-8.
Crossref Google Scholar
46

Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006; 126: 107-20.
Crossref Google Scholar
47

Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013; 155: 1216-9.
Crossref Google Scholar
48

Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7: 169-81.
Crossref Google Scholar
49

Paez J, Jänne P, Lee J, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-500.
Crossref Google Scholar
50

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2: 225-35.
Crossref Google Scholar
51

Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28: 357-60.
Crossref Google Scholar
52

Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019; 37: 876-84.
Crossref Google Scholar
53

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019; 25: 111-8.
Crossref Google Scholar
54

Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Giménez-Capitán A, Cantero F, et al. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun. 2019; 10: 1812.
Crossref Google Scholar
55

Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011; 6: e18691.
Crossref Google Scholar
56

Zou Y, Ling Y-H, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thorac Oncol. 2013; 8: 693-702.
Crossref Google Scholar
57

Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, et al. Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest. 2013; 93: 1137-46.
Crossref Google Scholar
58

Jutten B, Rouschop KMA. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle. 2014; 13: 42-51.
Crossref Google Scholar
59

Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1α and Bcl-2 and activating the Beclin 1/hVps34 complex. Cancer Res. 2010; 70: 5942-52.
Crossref Google Scholar
60

Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy. 2010; 6: 1066-77.
Crossref Google Scholar
61

Jutten B, Keulers TG, Peeters HJM, Schaaf MBE, Savelkouls KGM, Compter I, et al. EGFRvⅢ expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition. Autophagy. 2018; 14: 283-95.
Crossref Google Scholar
62

Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell. 2013; 154: 1269-84.
Crossref Google Scholar
63

Tan X, Thapa N, Sun Y, Anderson RA. A kinase-independent role for EGF receptor in autophagy initiation. Cell. 2015; 160: 145-60.
Crossref Google Scholar
64

Eimer S, Belaud-Rotureau MA, Airiau K, Jeanneteau M, Laharanne E, Véron N, et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther. 2011; 11: 1017-27.
Crossref Google Scholar
65

Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One. 2013; 8: 1-20.
Crossref Google Scholar
66

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-54.
Crossref Google Scholar
67

Maddodi N, Huang W, Havighurst T, Kim K, Longley BJ, Setaluri V, et al. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol. 2010; 130: 1657-67.
Crossref Google Scholar
68

Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013; 3: 1272-85.
Crossref Google Scholar
69

Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in Braf-driven cancers. Cancer Discov. 2014; 4: 766-72.
Crossref Google Scholar
70

Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 2014; 124: 1406-17.
Crossref Google Scholar
71

Levy JMM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, et al. Autophagy inhibition improves chemosensitivity in BRAFV600E brain tumors. Cancer Discov. 2014; 4: 773-80.
Crossref Google Scholar
72

Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, et al. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019; 10: 1693.
Crossref Google Scholar
73

Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol. 2019; 59: 23-35.
Crossref Google Scholar
74

Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011; 25: 460-70.
Crossref Google Scholar
75

Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell. 2011; 22: 165-78.
Crossref Google Scholar
76

Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, et al. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem. 2011; 286: 12924-32.
Crossref Google Scholar
77

Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013; 27: 1447-61.
Crossref Google Scholar
78

Fan Q, Yang L, Zhang X, Peng X, Wei S, Su D, et al. The emerging role of exosome-derived non-coding RNAs in cancer biology. Cancer Lett. 2018; 414: 107-15.
Crossref Google Scholar
79

Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018; 18: 5-18.
Crossref Google Scholar
80

Xu Z, Yan Y, Qian L, Gong Z. Long non-coding RNAs act as regulators of cell autophagy in diseases (Review). Oncol Rep. 2017; 37: 1359-66.
Crossref Google Scholar
81

Bermúdez M, Aguilar-Medina M, Lizárraga-Verdugo E, Avendaño-Félix M, Silva-Benítez E, López-Camarillo C, et al. LncRNAs as regulators of autophagy and drug resistance in colorectal cancer. Front Oncol. 2019; 9: 1008.
Crossref Google Scholar
82

Xiong H, Ni Z, He J, Jiang S, Li X, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017; 36: 3528-40.
Crossref Google Scholar
83

Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018; 9: 1149.
Crossref Google Scholar
84

Cai Q, Wang S, Jin L, Weng M, Zhou D, Wang J, et al. Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Mol Cancer. 2019; 18: 82.
Crossref Google Scholar
85

Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013; 73: 1180-9.
Crossref Google Scholar
86

Huang J, Yang Y, Fang F, Liu K. MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation. J Cell Biochem. 2018; 119: 3853-63.
Crossref Google Scholar
87

YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017; 16: 174.
Crossref Google Scholar
88

Huo J-F, Chen X-B. Long noncoding RNA growth arrest-specific 5 facilitates glioma cell sensitivity to cisplatin by suppressing excessive autophagy in an mTOR-dependent manner. J Cell Biochem. 2019; 120: 6127-36.
Crossref Google Scholar
89

Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2008; 7: 1013-30.
Crossref Google Scholar
90

Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013; 32: 805-18.
Crossref Google Scholar
91

Hetz C, Papa FR. The unfolded protein response and cell fate control. Mol Cell. 2018; 69: 169-81.
Crossref Google Scholar
92

Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012; 13: 89-102.
Crossref Google Scholar
93

Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008; 68: 498-505.
Crossref Google Scholar
94

Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 2005; 24: 3470-81.
Crossref Google Scholar
95

Görlach A, Klappa P, Kietzmann T. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal. 2006; 8: 1391-418.
Crossref Google Scholar
96

McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008; 11: 164-79.
Crossref Google Scholar
97

Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res. 2009; 69: 4415-23.
Crossref Google Scholar
98

Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, et al. ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012; 120: 1262-73.
Crossref Google Scholar
99

Yadav RK, Chae S-W, Kim H-R, Chae HJ. Endoplasmic reticulum stress and cancer. J Cancer Prev. 2014; 19: 75-88.
Crossref Google Scholar
100

Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003; 278: 9100-6.
Crossref Google Scholar
101

Fribley A, Zeng Q, Wang C. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stressreactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004; 24: 9695-704.
Crossref Google Scholar
102

Wroblewski D, Jiang CC, Croft A, Farrelly ML, Zhang XD, Hersey P. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PLoS One. 2013; 8: 1-13.
Crossref Google Scholar
103

Déry M-A, Jodoin J, Ursini-Siegel J, Aleynikova O, Ferrario C, Hassan S, et al. Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer. Breast Cancer Res. 2013; 15: R22.
Crossref Google Scholar
104

Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006; 31: 164-72.
Crossref Google Scholar
105

Corazzari M, Lovat PE, Armstrong JL, Fimia GM, Hill DS, Birch-Machin M, et al. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer. 2007; 96: 1062-71.
Crossref Google Scholar
106

Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5: 761-72.
Crossref Google Scholar
107

Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10: 537-49.
Crossref Google Scholar
108

Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta. 2004; 1699: 35-44.
Crossref Google Scholar
109

Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, et al. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res. 2008; 68: 5363-9.
Crossref Google Scholar
110

Tufo G, Jones AWE, Wang Z, Hamelin J, Tajeddine N, Esposti DD, et al. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ. 2014; 21: 685-95.
Crossref Google Scholar
111

Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol. 1997; 17: 5317-27.
Crossref Google Scholar
112

Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res. 1997; 57: 2661-7.
Google Scholar
113

Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol. 2003; 15: 419-24.
Crossref Google Scholar
114

Azad A, Zoubeidi A, Gleave M, Chi KN. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol. 2015; 12: 26-36.
Crossref Google Scholar
115

Roue G, Perez-Galan P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood. 2011; 117: 1270-9.
Crossref Google Scholar
116

Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013; 3: 430-43.
Crossref Google Scholar
117

Huot J, Houle F, Spitz DR, Landry J. HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Cancer Res. 1996; 56: 273-9.
Google Scholar
118

Chern Y, Zhang P, Ju H, Tai IT. Heat shock protein 47 promotes tumor survival and therapy resistance by modulating AKT signaling via PHLPP1 in colorectal cancer. Cancer Biol Med. 2020; 17: 343-56.
Crossref Google Scholar
119

Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013; 332: 275-85.
Crossref Google Scholar
120

Calderwood SK, Gong J. Molecular chaperones in mammary cancer growth and breast tumor therapy. J Cell Biochem. 2012; 113: 1096-103.
Crossref Google Scholar
121

Goloudina AR, Demidov ON, Garrido C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett. 2012; 325: 117-24.
Crossref Google Scholar
122

Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, et al. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011; 2: e221.
Crossref Google Scholar
123

Lamoureux F, Thomas C, Yin MJ, Zoubeidi A, Gleave ME. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol. 2014; 66: 145-55.
Crossref Google Scholar
124

Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, et al. Hsp27 inhibition with OGX-427 sensitizes non-small cell lung cancer cells to erlotinib and chemotherapy. Mol Cancer Ther. 2015; 14: 1107-16.
Crossref Google Scholar
125

Yu EY, Ellard SL, Hotte SJ, Gingerich JR, Joshua AM, Gleave ME, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018; 36: 278-87.
Crossref Google Scholar
126

Spigel DR, Shipley DL, Waterhouse DM, Jones SF, Ward PJ, Shih KC, et al. A randomized, double-blinded, phase Ⅱ trial of carboplatin and pemetrexed with or without apatorsen (OGX-427) in patients with previously untreated stage Ⅳ non-squamous-nonsmall-cell lung cancer: the SPRUCE trial. Oncologist. 2019; 24: e2409-16.
Crossref Google Scholar
127

Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, et al. A randomized, double-blinded, phase Ⅱ trial of gemcitabine and nab-paclitaxel plus apatorsen or placebo in patients with metastatic pancreatic cancer: the RAINIER trial. Oncologist. 2017; 22: 1427-e129.
Crossref Google Scholar
128

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, et al. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018; 118: 1434-41.
Crossref Google Scholar
129

Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, et al. Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2016; 15: 1043-52.
Crossref Google Scholar
130

Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007; 67: 3496-9.
Crossref Google Scholar
131

Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006; 66: 1702-11.
Crossref Google Scholar
132

Chern Y-J, Wong JCT, Cheng GSW, Yu A, Yin Y, Schaeffer DF, et al. The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2alpha and IRE1alpha/XBP-1 in colorectal cancer. Cell Death Dis. 2019; 10: 504.
Crossref Google Scholar
133

Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, Yokota T, et al. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett. 2002; 514: 122-8.
Crossref Google Scholar
134

Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003; 278: 20915-24.
Crossref Google Scholar
135

Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000; 403: 98-103.
Crossref Google Scholar
136

Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007; 67: 9809-16.
Crossref Google Scholar
137

Mozos A, Roué G, López-Guillermo A, Jares P, Campo E, Colomer D, et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am J Pathol. 2011; 179: 2601-10.
Crossref Google Scholar
138

Zhou H, Zhang Y, Fu Y, Chan L, Lee AS. Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK). J Biol Chem. 2011; 286: 25687-96.
Crossref Google Scholar
139

Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J. 2011; 434: 181-8.
Crossref Google Scholar
140

Lin Y, Wang Z, Liu L, Chen L. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer. 2011; 71: 291-7.
Crossref Google Scholar
141

Zhang LH, Yang XL, Zhang X, Cheng JX, Zhang W. Association of elevated GRP78 expression with increased astrocytoma malignancy via Akt and ERK pathways. Brain Res. 2011; 1371: 23-31.
Crossref Google Scholar
142

Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, et al. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol. 2011; 153: 741-52.
Crossref Google Scholar
143

Gray MJ, Mhawech-Fauceglia P, Yoo E, Yang W, Wu E, Lee AS, et al. AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers. Int J Cancer. 2013; 133: 21-30.
Crossref Google Scholar
144

Misra UK, Gonzalez-Gronow M, Gawdi G, Wang F, Pizzo SV. A novel receptor function for the heat shock protein Grp78: silencing of Grp78 gene expression attenuates α2M*-induced signalling. Cell Signal. 2004; 16: 929-38.
Crossref Google Scholar
145

Misra UK, Deedwania R, Pizzo SV. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem. 2006; 281: 13694-707.
Crossref Google Scholar
146

Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755-63.
Crossref Google Scholar
147

Misra UK, Payne S, Pizzo SV. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem. 2011; 286: 1248-59.
Crossref Google Scholar
148

Philippova M, Ivanov D, Joshi MB, Kyriakakis E, Rupp K, Afonyushkin T, et al. Identification of proteins associating with glycosylphosphatidylinositol-anchored T-cadherin on the surface of vascular endothelial cells: role for Grp78/BiP in T-cadherin-dependent cell survival. Mol Cell Biol. 2008; 28: 4004-17.
Crossref Google Scholar
149

Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene. 2009; 28: 2324-36.
Crossref Google Scholar
150

Zhang Y, Tseng C-C, Tsai Y-L, Fu X, Schiff R, Lee AS. Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One. 2013; 8: e80071.
Crossref Google Scholar
151

Shu C, Sun F, Cho J, Lin CC, Liu PF, Chen PY, et al. GRP78 and Raf-1 cooperatively confer resistance to endoplasmic reticulum stress-induced apoptosis. J Cell Physiol. 2008; 215: 627-35.
Crossref Google Scholar
152

Kern J, Untergasser G, Zenzmaier C, Sarg B, Gastl G, Gunsilius E, et al. GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood. 2009; 114: 3960-7.
Crossref Google Scholar
153

Baumeister P, Dong D, Fu Y, Lee AS. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol Cancer Ther. 2009; 8: 1086-94.
Crossref Google Scholar
154

Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014; 14: 263-76.
Crossref Google Scholar
155

Mousa SA, Sudha T, Dyskin E, Dier U, Gallati C, Hanko C, et al. Stress resistant human embryonic stem cells as a potential source for the identification of novel cancer stem cell markers. Cancer Lett. 2010; 289: 208-16.
Crossref Google Scholar
156

Kang J, Shakya A, Tantin D. Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends Biochem Sci. 2009; 34: 491-9.
Crossref Google Scholar
157

Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007; 1: 389-402.
Crossref Google Scholar
158

Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-23.
Crossref Google Scholar
159

Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008; 68: 3243-50.
Crossref Google Scholar
160

Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010; 102: 1276-83.
Crossref Google Scholar
161

Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, et al. Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010; 70: 4655-65.
Crossref Google Scholar
162

Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014; 13: 497-512.
Crossref Google Scholar
163

Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506: 328-33.
Crossref Google Scholar
164

Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 2014; 21: 1119-31.
Crossref Google Scholar
165

Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat. 2010; 13: 109-18.
Crossref Google Scholar
166

Fujimoto A, Kawana K, Taguchi A, Adachi K, Sato M, Nakamura H, et al. Inhibition of endoplasmic reticulum (ER) stress sensors sensitizes cancer stem-like cells to ER stress-mediated apoptosis. Oncotarget. 2016; 7: 51854-64.
Crossref Google Scholar
167

van Galen P, Kreso A, Mbong N, Kent DG, Fitzmaurice T, Chambers JE, et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature. 2014; 510: 268-72.
Crossref Google Scholar
168

Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol. 2006; 26: 5688-97.
Crossref Google Scholar
169

Wey S, Luo B, Lee AS. Acute inducible ablation of GRP78 reveals its role in hematopoietic stem cell survival, lymphogenesis and regulation of stress signaling. PLoS One. 2012; 7: e39047.
Crossref Google Scholar
170

Wu M-J, Jan C-I, Tsay Y-G, Yu YH, Huang CY, Lin SC, et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer. 2010; 9: 283.
Crossref Google Scholar
171

Chiu C, Lee L, Li Y, Chen YJ, Lu YC, Li YL, et al. Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-) CD44(+) stemness phenotype. Cancer Gene Ther. 2013; 20: 606-15.
Crossref Google Scholar
172

Wang N, Wang Z, Peng C, You J, Shen J, Han S, et al. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling. Carcinogenesis. 2014; 35: 2544-54.
Crossref Google Scholar
173

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-15.
Crossref Google Scholar
174

Morel A-P, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008; 3: e2888.
Crossref Google Scholar
175

Lehmann K, Janda E, Pierreux CE, Rytömaa M, Schulze A, McMahon M, et al. Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 2000; 14: 2610-22.
Crossref Google Scholar
176

Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Angela Nieto M. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004; 18: 1131-43.
Crossref Google Scholar
177

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12: 4147-53.
Crossref Google Scholar
178

Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54.
Crossref Google Scholar
179

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31: 277-83.
Crossref Google Scholar
180

Shah PP, Dupre TV, Siskind LJ, Beverly LJ. Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress. Oncotarget. 2017; 8: 22625-39.
Crossref Google Scholar
181

Tanjore H, Cheng D-S, Degryse AL, Zoz DF, Abdolrasulnia R, Lawson WE, et al. Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in response to endoplasmic reticulum stress. J Biol Chem. 2011; 286: 30972-80.
Crossref Google Scholar
182

Zeindl-Eberhart E, Brandl L, Liebmann S, Ormanns S, Scheel SK, Brabletz T, et al. Epithelial-mesenchymal transition induces endoplasmic-reticulum-stress response in human colorectal tumor cells. PLoS One. 2014; 9: e87386.
Crossref Google Scholar
183

Shen X, Xue Y, Si Y, Wang Q, Wang Z, Yuan J, et al. The unfolded protein response potentiates epithelial-to-mesenchymal transition (EMT) of gastric cancer cells under severe hypoxic conditions. Med Oncol. 2014; 32: 447.
Crossref Google Scholar
184

Feng Y, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JHL, Proia TA, et al. Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stress. Cancer Discov. 2014; 4: 702-15.
Crossref Google Scholar
185

Acosta JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol. 2012; 22: 211-9.
Crossref Google Scholar
186

Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010; 24: 2463-79.
Crossref Google Scholar
187

Salama R, Sadaie M, Hoare M, Narita M. Cellular senescence and its effector programs. Genes Dev. 2014; 28: 99-114.
Crossref Google Scholar
188

Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5: 99-118.
Crossref Google Scholar
189

Cahu J, Bustany S, Sola B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis. 2012; 3: e446.
Crossref Google Scholar
190

Burton DGA, Giribaldi MG, Munoz A, Halvorsen K, Patel A, Jorda M, et al. Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells. PLoS One. 2013; 8: e68003.
Crossref Google Scholar
191

Sun X, Shi B, Zheng H, Min L, Yang J, Li X, et al. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway. Cell Death Dis. 2018; 9: 260.
Crossref Google Scholar
192

Niu L-L, Cheng C, Li M-Y, Yang SL, Hu BG, Chong CCN, et al. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib. Cell Death Dis. 2018; 9: 852.
Crossref Google Scholar
193

Mastri M, Tracz A, Lee CR, Dolan M, Attwood K, Christensen JG, et al. A transient pseudosenescent secretome promotes tumor growth after antiangiogenic therapy withdrawal. Cell Rep. 2018; 25: 3706-20.e8.
Crossref Google Scholar
194

Sidi R, Pasello G, Opitz I, Soltermann A, Tutic M, Rehrauer H, et al. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur J Cancer. 2011; 47: 326-32.
Crossref Google Scholar
195

Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 2012; 31: 3148-63.
Crossref Google Scholar
196

Martino S di, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, et al. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene. 2018; 37: 1369-85.
Crossref Google Scholar
197

Davies KJA. Adaptive homeostasis. Mol Aspects Med. 2016; 49: 1-7.
Crossref Google Scholar
198

Fitzwalter BE, Thorburn A. Recent insights into cell death and autophagy. FEBS J. 2015; 282: 4279-88.
Crossref Google Scholar
199

Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase Ⅱ and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014; 19: 637-8.
Crossref Google Scholar
200

Sonneveld P, Schmidt-Wolf IGH, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase Ⅲ HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30: 2946-55.
Crossref Google Scholar
201

Huntsman DG, Ladanyi M. The molecular pathology of cancer: from pan-genomics to post-genomics. J Pathol. 2018; 244: 509-11.
Crossref Google Scholar
202

Gorgoulis VG, Pefani D-E, Pateras IS, Trougakos IP. Integrating the DNA damage and protein stress responses during cancer development and treatment. J Pathol. 2018; 246: 12-40.
Crossref Google Scholar
203

Bian S, Hou Y, Zhou X, Li X, Yong J, Wang Y, et al. Single-cell multiomics sequencing and analyses of human colorectal cancer. Science. 2018; 362: 1060-3.
Crossref Google Scholar
204

Hu X, Shi S, Wang H, Yu X, Wang Q, Jiang S, et al. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Sci Rep. 2017; 7: 4559.
Crossref Google Scholar
205

Abdul Rahim SA, Dirkse A, Oudin A, Schuster A, Bohler J, Barthelemy V, et al. Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. Br J Cancer. 2017; 117: 813-25.
Crossref Google Scholar
206

Muñoz-Galván S, Gutierrez G, Perez M, Carnero A. MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFκB activation in breast cancer. Mol Cancer Ther. 2015; 14: 1454-65.
Crossref Google Scholar
207

Rupniewska E, Roy R, Mauri FA, Liu X, Kaliszczak M, Bellezza G, et al. Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget. 2018; 9: 27346-62.
Crossref Google Scholar
208

Yeh ES, Abt MA, Hill EG. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors. Breast Cancer Res Treat. 2015; 149: 91-8.
Crossref Google Scholar
209

Pan H, Wang Z, Jiang L, Sui X, You L, Shou J, et al. Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci Rep. 2014; 4: 6683.
Crossref Google Scholar
210

Li L, Wang Y, Jiao L, Lin C, Lu C, Zhang K, et al. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Lett. 2019; 452: 191-202.
Crossref Google Scholar
211

Zheng B, Zhu H, Gu D, Pan X, Qian L, Xue B, et al. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun. 2015; 459: 234-9.
Crossref Google Scholar
212

Lu S, Yao Y, Xu G, Zhou C, Zhang Y, Sun J, et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 2018; 9: 646.
Crossref Google Scholar
213

Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, et al. HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy. 2018; 14: 2155-70.
Crossref Google Scholar
214

Wiedmer T, Blank A, Pantasis S, Normand L, Bill R, Krebs P, et al. Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via A lysosome-dependent mechanism. Mol Cancer Ther. 2017; 16: 2502-15.
Crossref Google Scholar
215

Ojha R, Leli NM, Onorati A, Piao S, Verginadis Ⅱ, Tameire F, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF-mutant melanoma. Cancer Discov. 2019; 9: 396-415.
Crossref Google Scholar
216

Altman JK, Szilard A, Goussetis DJ, Sassano A, Colamonici M, Gounaris E, et al. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res. 2014; 20: 2400-9.
Crossref Google Scholar
217

Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One. 2009; 4: e6251.
Crossref Google Scholar
218

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, López-Bonet E, et al. The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep. 2013; 3: 2469.
Crossref Google Scholar
219

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, et al. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget. 2012; 3: 1600-14.
Crossref Google Scholar
220

Martin S, Dudek-Perić AM, Maes H, Garg AD, Gabrysiak M, Demirsoy S, et al. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochem Pharmacol. 2015; 93: 290-304.
Crossref Google Scholar
221

Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, et al. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Autophagy. 2015; 11: 355-72.
Crossref Google Scholar
222

Kumandan S, Mahadevan NR, Chiu K, DeLaney A, Zanetti M. Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. Cancer Lett. 2013; 329: 236-42.
Crossref Google Scholar
223

Sui X, Kong N, Wang X, Fang Y, Hu X, Xu Y, et al. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep. 2014; 4: 4694.
Crossref Google Scholar
224

Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer. 2010; 46: 1900-9.
Crossref Google Scholar
225

Ou J, Peng Y, Yang W, Zhang Y, Hao J, Li F, et al. ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. Nat Commun. 2019; 10: 1078.
Crossref Google Scholar
226

Takahashi H, Inoue J, Sakaguchi K, Takagi M, Mizutani S, Inazawa J, et al. Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. Oncogene. 2017; 36: 4267-76.
Crossref Google Scholar
227

Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 2014; 289: 17163-73.
Crossref Google Scholar
228

Yu L, Gu C, Zhong D, Shi L, Kong Y, Zhou Z, et al. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett. 2014; 355: 34-45.
Crossref Google Scholar
229

Braggio D, Koller D, Jin F, Siva N, Zewdu A, Lopez G, et al. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors. Cancer. 2019; 125: 2693-703.
Crossref Google Scholar
230

Pan X, Chen Y, Shen Y, Tantai J. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7. Cell Death Dis. 2019; 10: 429.
Crossref Google Scholar
231

Ma H, Li Y, Wang X, Wu H, Qi G, Li R, et al. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma. Cell Death Dis. 2019; 10: 166.
Crossref Google Scholar
232

Jiang L, Xu L, Xie J, Li S, Guan Y, Zhang Y, et al. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells. Cancer Biol Ther. 2015; 16: 466-76.
Crossref Google Scholar
233

Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, et al. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J Cancer. 2015; 112: 832-40.
Crossref Google Scholar
234

Yang M, Zeng P, Kang R, Yu Y, Yang L, Tang D, et al. S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. PLoS One. 2014; 9: e97242.
Crossref Google Scholar
235

Jaganathan S, Malek E, Vallabhapurapu S, Vallabhapurapu S, Driscoll JJ. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells. Oncotarget. 2014; 5: 12358-70.
Crossref Google Scholar
236

Armstrong JL, Corazzari M, Martin S, Pagliarini V, Falasca L, Hill DS, et al. Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition. Clin Cancer Res. 2011; 17: 2216-26.
Crossref Google Scholar
237

Hu F, Zhao Y, Yu Y, Fang JM, Cui R, Liu ZQ, et al. Docetaxelmediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3. Cancer Lett. 2018; 416: 24-30.
Crossref Google Scholar
238

Nguyen HG, Yang JC, Kung H-J, Shi XB, Tilki D, Lara PN Jr, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014; 33: 4521-30.
Crossref Google Scholar
239

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, et al. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res. 2014: 3159-73.
Crossref Google Scholar
240

Sun W-L, Chen J, Wang Y-P, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy. 2011; 7: 1035-44.
Crossref Google Scholar
241

Song B, Bian Q, Shao CH, Li G, Liu AA, Jing W, et al. Ulinastatin reduces the resistance of liver cancer cells to epirubicin by inhibiting autophagy. PLoS One. 2015; 10: e0120694.
Crossref Google Scholar
242

Pan B, Chen Y, Song H, Xu Y, Wang R, Chen L. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget. 2015; 6: 317-31.
Crossref Google Scholar
243

Ma T, Chen W, Zhi X, Liu H, Zhou Y, Chen BW, et al. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Cancer Lett. 2018; 436: 129-38.
Crossref Google Scholar
244

Zhang J, Zhang S, Song J, Sun K, Zong C, Zhao Q-D, et al. Autophagy inhibition switches low-dose camptothecin-induced premature senescence to apoptosis in human colorectal cancer cells. Biochem Pharmacol. 2014; 90: 265-75.
Crossref Google Scholar
245

Liu W, Zhang Z, Zhang Y, Chen X, Guo S, Lei Y, et al. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biol Ther. 2015; 16: 511-7.
Crossref Google Scholar
246

Peng X, Gong F, Chen Y, Jiang Y, Liu J, Yu M, et al. Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-α-mediated signaling. Cell Death Dis. 2014; 5: e1367.
Crossref Google Scholar
247

Taylor P. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 2015; 11: 37-41.
Crossref Google Scholar
248

Wen J, Yeo S, Wang C, Chen S, Sun S, Hass MA, et al. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis. Breast Cancer Res Treat. 2015; 149: 619-29.
Crossref Google Scholar
249

Tong Y, Huang H, Pan H. Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2015; 456: 86-91.
Crossref Google Scholar
250

Chen R, Dai RY, Duan CY, Liu YP, Chen SK, Yan DM, et al. Unfolded protein response suppresses cisplatin-induced apoptosis via autophagy regulation in human hepatocellular carcinoma cells. Folia Biol (Praha). 2011; 57: 87-95.
Google Scholar
251

Sisinni L, Maddalena F, Lettini G, Condelli V, Swann D, Esposito F, et al. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. Int J Oncol. 2014; 44: 573-82.
Crossref Google Scholar
252

Wang L, Zhang Y, Wang W, Zhu Y, Chen Y, Tian B. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). PLoS One. 2017; 12: e0184110.
Crossref Google Scholar
253

Roemeling CA von, Marlow LA, Kennedy WP, Kennedy GT, Copland JA, Menefee ME. Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma. Am J Cancer Res. 2013; 3: 390-401.
Google Scholar
254

Wang J, Yin Y, Hua H, Li M, Luo T, Xu L, et al. Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response. J Cell Mol Med. 2009; 13: 3888-97.
Crossref Google Scholar
255

Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, Piscazzi A, et al. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol. 2013; 7: 895-906.
Crossref Google Scholar
256

Notte A, Rebucci M, Fransolet M, Roegiers E, Genin M, Tellier C, et al. Taxol-induced unfolded protein response activation in breast cancer cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis. Int J Biochem Cell Biol. 2015; 62: 1-14.
Crossref Google Scholar
257

Mhaidat NM, Thorne R, Zhang XD, Hersey P. Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis. 2008; 13: 1505-12.
Crossref Google Scholar
258

Strzeszewska A, Alster O, Mosieniak G, Ciolko A, Sikora E. Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells. Cell Death Dis. 2018; 9: 44.
Crossref Google Scholar
259

Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, et al. Chemotherapy-induced inflammatory gene signature and protumorigenic phenotype in pancreatic CAFs via stress-associated MAPK. Mol Cancer Res. 2016; 14: 437-47.
Crossref Google Scholar
260

Martínez J, Tarallo D, Martínez-Palma L, Victoria S, Bresque M, Rodríguez-Bottero S, et al. Mitofusins modulate the increase in mitochondrial length, bioenergetics and secretory phenotype in therapy-induced senescent melanoma cells. Biochem J. 2019; 476: 2463-86.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 17 Issue 4,
November 2020
Pages 842-863
DOI: 10.20892/j.issn.2095-3941.2020.0005
Cite this article:
Chern Y-J, Tai IT. Adaptive response of resistant cancer cells to chemotherapy. Cancer Biology & Medicine, 2020, 17(4): 842-863. https://doi.org/10.20892/j.issn.2095-3941.2020.0005

63

Views

2

Downloads

31

Crossref

N/A

Web of Science

28

Scopus

Altmetrics
Received: 25 November 2019
Accepted: 27 April 2020
Published: 15 November 2020
©2020 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return